Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

References

• Siegel SE, Stock W, Johnson RH, et al. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol. 2018;4(5):725–734.
   PubMed Web of Science ®Google Scholar
• Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012;87(5):472–478.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–534.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548. blood-2018-10-881961.
   PubMed Web of Science ®Google Scholar
• Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009;7:600–606.
   PubMedGoogle Scholar
• Sallan SE, Gelber RD, Kimball V, et al. More is better! Update of Dana-Farber Cancer Institute/Children’s Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990;33:459–466.
   PubMedGoogle Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–342.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554–563.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–2253.
   PubMed Web of Science ®Google Scholar
• Asselin BL. L-asparaginase for treatment of childhood acute lymphoblastic leukemia: what have we learned? (Commentary on Schrey et al., page 378). Pediatr Blood Cancer. 2011;57(3):357–358.
   PubMed Web of Science ®Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and Leukemia Group B Study 9511. Blood. 2007;109(10):4164–4167.
   PubMed Web of Science ®Google Scholar
• Kumar AJ, Gimotty PA, Gelfand JM, et al. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol. 2016;91(11):1107–1112.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pullarkat V, Martinez D, et al. The number of peg-asparaginase doses administered is a determinant of relapse risk in adult ALL treated with a pediatric-like regimen. Blood. 2013;122(21):3915–3915.
   Web of Science ®Google Scholar
• Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018;24(4):299–308.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351–1353.
   PubMed Web of Science ®Google Scholar
• Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children’s Oncology Group Study AALL0232. JCO. 2016;34(20):2380–2388.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744–2750.
   PubMed Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279–285.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367–393.
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. Favorable outcomes for older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): early results of U.S. Intergroup Trial C10403. Blood. 2014;124(21):796–796.
   Web of Science ®Google Scholar
• Schore RJ, Devidas M, Bleyer A, et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4. Leuk Lymphoma. 2019;60:1740–1748.
   PubMed Web of Science ®Google Scholar
• Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797–1806.
   PubMed Web of Science ®Google Scholar
• Ribera J-M, Oriol A, Sanz M-A, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. JCO. 2008;26(11):1843–1849.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. JCO. 2009;27(6):911–918.
   PubMed Web of Science ®Google Scholar
• Advani AS, Sanford B, Luger S, et al. Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance). Blood. 2013;122(21):3903–3903.
   Web of Science ®Google Scholar
• Alshiekh-Nasany R, Douer D. L-carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol. 2016;135(4):208–210.
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Goodman A, Jonas BA, et al. L-carnitine for pegylated-l-asparaginase induced hepatotoxicity. JCO. 2017;35(15_suppl):e21626–e21626.
   Google Scholar
• Huguet F, Chevret S, Leguay T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. JCO. 2018;36(24):2514–2523.
   PubMed Web of Science ®Google Scholar
• Alachkar H, Fulton N, Sanford B, et al. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017;17(3):274–279.
   PubMed Web of Science ®Google Scholar
• Oncaspar Prices, Coupons & Patient Assistance Programs [Internet]. Drugs.com. [cited 2019 Jan 18]. Available from: https://www.drugs.com/price-guide/oncaspar.
   Google Scholar
• Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–248.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour EJ, Ravandi F, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, for newly diagnosed older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: results from a phase II study. Blood. 2018;132:36–36.
   Web of Science ®Google Scholar
• Richard-Carpentier G, Kantarjian HM, Short NJ, et al. A phase II study of the hyper-CVAD regimen in sequential combination with blinatumomab as frontline therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2018;132:32–32.
   Web of Science ®Google Scholar